Enzolytics, Inc. is a drug development company. The Company is focused on commercializing its licensed proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases to include the additional contracted areas of sales, marketing and distribution of medical devices, medical testing and nutraceutical products. Its subsidiaries include BioClonetics lmmunotherapy, Inc. and Biogenysis, Inc.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-21	US$0.000600	-.--%	752,588
26-08-20	US$0.000600	-14.29%	899,444
26-08-19	US$0.000700	-.--%	916,634
26-08-18	US$0.000700	+16.67%	504,147
26-08-17	US$0.000600	-.--%	912,570

Real-time OTC Markets

More quotes

Market Closed - OTC Markets 14:44:28 2026-06-04 EDT			5-day change	1st Jan Change
0.000800 ^USD	-20.00%		+33.33%	+166.67%

24-07-31	Enzolytics, Inc. and the Bulgaria Academy of Sciences Initiate A Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/A Applications	CI
24-07-29	Enzolytics, Inc. Enters into Collaboration Agreement with Manufacturer Elimus Ltd	CI

Market Cap	132K 113K 106K 97K 182K 12.65M 184K 1.25M 488K 6.35M 496K 486K 21.02M	P/E 2009 *	-	P/E 2010	-0.29x
Enterprise Value	460K 394K 369K 337K 633K 44M 642K 4.35M 1.7M 22.1M 1.73M 1.69M 73.11M	EV / Sales 2009	325,315,067x	EV / Sales 2010	210,445,953x
Free-Float	100%	Yield 2009 *	-	Yield 2010	-

24-07-31	Enzolytics, Inc. and the Bulgaria Academy of Sciences Initiate A Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/A Applications	CI
24-07-29	Enzolytics, Inc. Enters into Collaboration Agreement with Manufacturer Elimus Ltd	CI
24-05-02	Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment LLC	CI
24-03-25	Enzolytics, Inc. Announces Board Changes	CI
24-03-25	Enzolytics, Inc Appoints Diana Zhabilov as Chief Financial Officer	CI
24-03-25	Enzolytics, Inc Appoints Steven Sharabura as Chief Executive Officer	CI
23-06-26	Enzolytics Offers Update on Virogentics, Inc ITV-1 African Project	CI
23-04-21	Enzolytics, Inc. Provides Update on Clinical Trials	CI
23-04-16	Biogenysis, Inc. & Virogentics, Inc. executed a non-binding term sheet to acquire Sagaliam Acquisition Corp. from Lighthouse Investment Partners, LLC, Enzolytics, Inc., Sagaliam Sponsor LLC, GLD Sponsor Member, LLC, AHG Equities LLC and others for $450 million in a reverse merger transaction.	CI
23-02-08	Enzolytics Announces Preliminary Results of GLP Toxicology Study for its anti-HIV Therapeutic ITV-1 and Production of ITV-1 for Initiation of Registration in Africa	CI
23-01-03	Enzolytics to Develop Feline Monoclonal Antibodies	CI
22-12-13	Enzolytics, Inc. Announces U.S. Distribution of IPF Immune(TM) and Progress in each of its Therapeutic Platforms	CI
22-11-16	Enzolytics, Inc. Announces Expansion of Production of Its Monoclonal Antibody Therapeutics and Marketing of IPF Immune	CI

24-08-05	Penny Stocks to Watch August 2024: SPZI, RJDG, HIRU, AABB more inside...	AQ
24-03-28	Stocks Under 5¢ Watch Now! CLNV, HNRC, HALB, ENZC, RSHN	AQ
24-03-12	RushNet (OTC: RSHN) and Royal Caridea Join Forces to Transform Aquaculture Harvesting Shrimp and more...SPZI, HALB, ENZC, HNRC	AQ
24-03-01	Stocks Under 5¢ To Watch Now! HNRC, HALB, ENZC, SNNC, SPZI	AQ
24-02-07	OTC Stocks to Watch in February: CLNV, HNRC, ENZC, GEVI, PBIO	AQ

Enzolytics, Inc. Stock

Stocks

ENZC

US2941121079

Biotechnology & Medical Research

Valuation: Enzolytics, Inc.

Chart: Enzolytics, Inc.

Latest news : Enzolytics, Inc.

Press Releases: Enzolytics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Enzolytics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 day	-20.00%
1 week	+33.33%
Current month	+33.33%
1 month	+33.33%
3 months	+60.00%
6 months	+33.33%
Current year	+166.67%

Manager	Title	Age	Since
Steven Sharabura CEO	Chief Executive Officer	-	2024-03-20
Diana Zhabilov DFI	Director of Finance/CFO	-	2024-03-20
Harry Zhabilov CEO	Chief Executive Officer	59	2017-06-15

Director	Title	Age	Since
Harry Zhabilov CHM	Chairman	59	2024-03-18
Lachezar Ivanov BRD	Director/Board Member	-	2024-03-18

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENZOLYTICS, INC.	-20.00%	+33.33%	+33.33%	-98.00%	2.9M
WUXI APPTEC CO., LTD.	-3.00%	+2.27%	+73.26%	+113.08%	72.12B
ARGENX SE	+1.90%	+23.53%	+59.48%	+94.94%	65.85B
BIONTECH SE	+5.12%	+25.22%	+5.13%	-5.23%	29.28B
INSMED INCORPORATED	+0.55%	+1.64%	-4.63%	+469.35%	27.47B
WUXI BIOLOGICS (CAYMAN) INC.	-5.10%	+5.07%	+45.73%	+8.74%	26.7B
GENMAB A/S	+0.47%	+6.12%	+37.01%	-16.17%	20.06B
PHARMAESSENTIA CORPORATION	+1.82%	-6.67%	+251.36%	+388.91%	18.22B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.32%	+1.05%	+12.39%	+555.90%	16.4B
EXELIXIS, INC.	+0.73%	+5.54%	+39.99%	+148.64%	13.4B
Average	-1.92%	+7.53%	+55.30%	+166.02%	28.95B
Weighted average by Cap.	-0.12%	+9.48%	+57.01%	+156.31%

	2009	2010
Net sales	0.01 0.01 0.01 0.01 0.02 1.41 0.02 0.14 0.05 0.71 0.06 0.05 2.34	0.04 0.03 0.03 0.03 0.05 3.54 0.05 0.35 0.14 1.78 0.14 0.14 5.88
Net income	-970K -831K -777K -712K -1.34M -92.79M -1.35M -9.18M -3.58M -46.61M -3.64M -3.56M -154M	-7.51M -6.44M -6.02M -5.51M -10.35M -719M -10.48M -71.15M -27.75M -361M -28.21M -27.6M -1.19B
Net Debt	924K 791K 740K 678K 1.27M 88.38M 1.29M 8.75M 3.41M 44.4M 3.47M 3.39M 147M	328K 281K 263K 240K 451K 31.35M 457K 3.1M 1.21M 15.75M 1.23M 1.2M 52.09M